BCL2 and breast cancer: Consequently, these findings reveal that TRIM25 promotes ubiquitination-mediated degradation of BRD7 and promotes breast cancer progression and paclitaxel resistance via the YB1-Bcl-2 axis, which provides a new prognostic predictor and therapeutic target for breast cancer.